<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387581</url>
  </required_header>
  <id_info>
    <org_study_id>20101</org_study_id>
    <nct_id>NCT01387581</nct_id>
  </id_info>
  <brief_title>Does the Aid of MelaFind Affect Clinical Management Decisions</brief_title>
  <official_title>To Excise or Not?: Comparing Clinical Management Decisions for Melanoma Between Dermatologists With and Without the Aid of MelaFind</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MELA Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MELA Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine and compare the performance of dermatologists (in
      Germany) on the excision decision against the performance of MelaFind, a non-invasive and
      objective multi-spectral computer vision system designed as a tool to aid dermatologists in
      the detection of early melanoma. The hypothesis is that MelaFind's sensitivity is superior to
      the average excisions sensitivity of dermatologists.

      Another objective is to determine and compare the performance of dermatologists (in Germany)
      with and without the aid of MelaFind. The hypothesis is that the average excision sensitivity
      of dermatologists with the aid of MelaFind is superior to the average excision sensitivity of
      dermatologists without the aid of MelaFind.

      A similar study was previously conducted with dermatologists in the US (NCT01011153). An
      exploratory objective is to compare the excision decisions of dermatologists from the
      previous study (in the US) to dermatologists in in this study (in Germany).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early detection of melanoma is critical for favorable prognosis, since patients with earlier
      stage melanomas have a much higher probability of survival than with later stages. The
      traditional method of early detection has been with serial total body skin exams where the
      health care provider examines all skin surfaces, including mucosa, for suspicious pigmented
      lesions. The diagnostic performance of dermatologists for melanoma depends on the level of
      dermatological training. More important than being able to make a diagnosis of melanoma on
      clinical impression is the ability to make an appropriate decision to excise the lesion. To
      aid dermatologists in the detection of early melanoma, MelaFind was developed, a non-invasive
      and objective multi-spectral computer vision system technology. It was designed to generate
      output - MelaFind Positive or MelaFind Negative- for consideration in the lesion management
      decisions.

      This survey study will determine and compare the average excision sensitivity to melanoma and
      specificity of dermatologists (in Germany) without MelaFind output to the average excision
      sensitivity to melanoma and specificity of dermatologists (in Germany) with MelaFind output.
      Another purpose is to determine and compare the sensitivity to melanoma and specificity of
      MelaFind to the average excision sensitivity to melanoma and specificity of dermatologists
      without MelaFind output.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>Within 120 days of Data Lock</time_frame>
    <description>Dermatologist sensitivity is the percent of melanomas that dermatologists selected to biopsy. MelaFind sensitivity is the percent of melanomas that MelaFind called &quot;Positive.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>Within 120 days of Data Lock</time_frame>
    <description>Dermatologist specificity is the percent of non-melanomas that dermatologists selected not to biopsy. MelaFind specificity is the percent of non-melanomas that MelaFind called &quot;Negative.&quot;</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">227</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Without MelaFind</arm_group_label>
    <description>Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>With MelaFind</arm_group_label>
    <description>Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experts Without MelaFind</arm_group_label>
    <description>PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        130 dermatologists will enter by way of general invitation and will be randomly placed in
        either Arm 1 (Without MelaFind) or Arm 2 (With MelaFind). Another group, up to 30 Pigmented
        Skin Lesion Experts, will be prospectively identified by the Principal Investigator of this
        study prior to any participant recruitment, and will be invited to participate in the study
        by the PI after the general recruitment is completed.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Only board certified dermatologists

        Exclusion Criteria:

        -May not have previously participated in MELA Protocols 20061, 20081 or 20063
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Hauschild, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatologic Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MELA Sciences</name>
      <address>
        <city>Irvington</city>
        <state>New York</state>
        <zip>10533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2011</study_first_posted>
  <results_first_submitted>April 3, 2014</results_first_submitted>
  <results_first_submitted_qc>November 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 14, 2014</results_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dermatologists were selected at random from Germany's public dermatology membership list and were invited to participate by letter. Those interested in participating were asked to register online. Eligible dermatologists were selected to participate on a first-come basis and were divided by random placement into one of two study arms.</recruitment_details>
      <pre_assignment_details>Dermatologists interested in participating were asked to register online by responding to an Intake Survey. The survey included questions about dermatology training, medical licensure, board certification, and comfort with and frequency of screening for melanoma. Only board certified dermatologists were permitted to participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Without MelaFind</title>
          <description>Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
        </group>
        <group group_id="P2">
          <title>With MelaFind</title>
          <description>Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion</description>
        </group>
        <group group_id="P3">
          <title>Experts Without MelaFind</title>
          <description>PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Without MelaFind</title>
          <description>Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
        </group>
        <group group_id="B2">
          <title>With MelaFind</title>
          <description>Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion</description>
        </group>
        <group group_id="B3">
          <title>Experts Without MelaFind</title>
          <description>PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>31-40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51-60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dermoscopy use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rarely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; half of pigmented skin lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; half of pigmented skin lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Almost all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Always</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years in Practice</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 - 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 - 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity</title>
        <description>Dermatologist sensitivity is the percent of melanomas that dermatologists selected to biopsy. MelaFind sensitivity is the percent of melanomas that MelaFind called &quot;Positive.&quot;</description>
        <time_frame>Within 120 days of Data Lock</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Without MelaFind</title>
            <description>Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
          </group>
          <group group_id="O2">
            <title>With MelaFind</title>
            <description>Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion</description>
          </group>
          <group group_id="O3">
            <title>Experts Without MelaFind</title>
            <description>PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity</title>
          <description>Dermatologist sensitivity is the percent of melanomas that dermatologists selected to biopsy. MelaFind sensitivity is the percent of melanomas that MelaFind called &quot;Positive.&quot;</description>
          <units>percent of true positives</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" lower_limit="64.3" upper_limit="76.0"/>
                    <measurement group_id="O2" value="78.0" lower_limit="73.9" upper_limit="83.5"/>
                    <measurement group_id="O3" value="71.8" lower_limit="66.3" upper_limit="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity</title>
        <description>Dermatologist specificity is the percent of non-melanomas that dermatologists selected not to biopsy. MelaFind specificity is the percent of non-melanomas that MelaFind called &quot;Negative.&quot;</description>
        <time_frame>Within 120 days of Data Lock</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Without MelaFind</title>
            <description>Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
          </group>
          <group group_id="O2">
            <title>With MelaFind</title>
            <description>Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion</description>
          </group>
          <group group_id="O3">
            <title>Experts Without MelaFind</title>
            <description>PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity</title>
          <description>Dermatologist specificity is the percent of non-melanomas that dermatologists selected not to biopsy. MelaFind specificity is the percent of non-melanomas that MelaFind called &quot;Negative.&quot;</description>
          <units>percent of true negatives</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" lower_limit="47.3" upper_limit="60.5"/>
                    <measurement group_id="O2" value="45.8" lower_limit="38.1" upper_limit="50.8"/>
                    <measurement group_id="O3" value="54.6" lower_limit="46.3" upper_limit="59.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Without MelaFind</title>
          <description>Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
        </group>
        <group group_id="E2">
          <title>With MelaFind</title>
          <description>Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion</description>
        </group>
        <group group_id="E3">
          <title>Experts Without MelaFind</title>
          <description>PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation of this study is the reader study format. Lesions were presented to participating dermatologists as photographs via the online system. This presentation can only approximate an in-person clinical exam.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mrinalini Roy</name_or_title>
      <organization>MelaSciences</organization>
      <phone>800-729-8849</phone>
      <email>mishti@melasciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

